A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
- Conditions
- Neuroendocrine TumorsPancreatic Neoplasms
- Interventions
- Drug: TH-302 + Sunitinib
- Registration Number
- NCT02402062
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Brief Summary
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
- Detailed Description
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in Treatment-naïve patients with well- and moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
-
Male or female, 18 years of age or older.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of ≤ 20% (well and moderately differentiated)
-
Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.
-
Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.
-
Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit.
-
Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
-
Patient has to be able to swallow the medication.
-
Life expectancy greater than 12 weeks.
-
The definitions of minimum adequacy for organ function required prior to study entry are as follows:
- Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
- Total serum bilirubin ≤ 1.5 x ULN
- Serum albumin ≥ 3.0 g/dL
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL)
- Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)
-
Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal multiple gated acquisition scan (MUGA) (LVEF> 50%)
-
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
-
Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, or interferon are not permitted for the advanced disease.
-
Prior treatment on another hypoxia-activated prodrug under clinical trial.
-
Major surgery, radiation therapy, or systemic therapy within 3 weeks of study randomization except palliative radiotherapy to non-target metastatic lesions.
-
Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
-
Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken concurrently or within last 3 months prior to randomization
-
Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that prolong the QT interval in the previous 7 days.
-
Prior radiation therapy to > 25% of the bone marrow.
-
Current treatment on another clinical trial.
-
Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months prior to first dose of treatment on study and should be asymptomatic.
-
Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
-
Any of the following within the 12 months prior to starting study treatment:
- myocardial infarction,
- severe/unstable angina,
- coronary/peripheral artery bypass graft,
- congestive heart failure class III or IV of the New York Heart Association (NYHA) or patients with clinical history of congestive heart failure class III or IV of the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection shows a LVEF ? 45 %
- significant heart valve disease
- cerebrovascular accident including transient ischemic attack
- pulmonary embolus.
-
Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE) grade ≥ 2, atrial fibrillation of any grade, or corrected QT interval (QTc) interval >450 msec for males or >470 msec for females.
-
Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
-
Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with hypoxemia or oxygen saturation < 90% after a march of two minutes.
-
Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
-
Known human immunodeficiency virus infection.
-
Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to inclusion.
-
Previous allergic reaction to components structurally similar to TH-302 or sunitinib or any of the excipients of drugs.
-
Non-healing wound, fistulae, active peptic ulcer or bone fracture.
-
Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TH-302 + Sunitinib TH-302 + Sunitinib TH-302 + Sunitinib. Single arm Study.
- Primary Outcome Measures
Name Time Method Objective Response Rate approximately 36 months Objective response rate: percentage of patients in whom a complete response (CR) or a partial response (PR) is confirmed according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in relation to the total of the analyzed population.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) approximately 36 months Time between the start of study treatment to date of the first objective evidence of radiological progression or patient death due to any cause; which comes first.
Time to Tumour Progression (TTP) approximately 36 months It is defined as the time between the start of study treatment to date of the first objective evidence of radiological progression.
Duration of Response (DR) approximately 36 months It is defined as the time between the start from the first documentation of objective response (CR or PR) which is subsequently confirmed until the first objective evidence of radiological progression or death from any cause. DR is calculated only in the subgroup of patients with an objective response (CR + PR).
Overall Survival (OR) approximately 36 months It is defined as the time between the start of study treatment to date of death from any cause. If it were impossible to obtain confirmation of the death, survival will be censored with the date of the last Visit that it is satisfied that the patient was alive.
Safety (Adverse Events) time between the date of signing the informed consent until 28 days after the last dose of study drug, , an average of 2 years Safety will be assessed according to the reports of adverse events, the frequency of treatment discontinuations due to adverse events, laboratory evaluations or ECG
Biomarkers in Serum and Tumor Tissue approximately 36 months Assess the predictive/prognostic value of the analysed biomarkers in plasm and tumour.
Trial Locations
- Locations (10)
Hospital Universitario Marqués de Valdecilla
🇪🇸Santander, Cantabria, Spain
Institut Catalá d'Oncologia L'Hospitalet
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario Virgen de las Nieves
🇪🇸Granada, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Hospital Universitario Virgen de la Victoria
🇪🇸Málaga, Spain
Hospital Provincial de Castellón
🇪🇸Castelló, Valencia, Spain